Business
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
CHALFONT ST GILES, England, April 23, 2026--GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation
About this update from Ge Aerospace
[{"type":"image","alt":"First-in-human contrast enhanced MRI images with GE HealthCare's mangaciclanol","displaySize":"","headline":null,"caption":"First-in-human contrast enhanced MRI images with GE HealthCare's mangaciclanol","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":319,"url":"https://media.zenfs.com/en/business-wire.com/7a66b68a4daf4332df2deaf535635696"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/P0EPp5WH2gPuyGgR8Lgwag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYzOA--/https://media.zenfs.com/en/business-wire.com/7a66b68a4daf4332df2deaf535635696","width":480,"height":319}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":800,"height":273,"url":"https://media.zenfs.com/en/business-wire.com/09f93c9477c2f60b3dab347dfc058658"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yQ2oJJKO3fVrpX7XwHNy8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyOA--/https://media.zenfs.com/en/business-wire.com/09f93c9477c2f60b3dab347dfc058658","width":800,"height":273},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/qhcNPlbmcVnVN1qcrRHaQg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MDA7aD01NDY-/https://media.zenfs.com/en/business-wire.com/09f93c9477c2f60b3dab347dfc058658","width":800,"height":273}}},{"type":"list","items":[{"val":[{"type":"text","content":"Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents","length":152,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"A manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designation","length":243,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs","length":116,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":511,"olType":false},{"type":"text","content":"CHALFONT ST GILES, England, April 23, 2026--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi...